Jay Gelfman - MaxCyte Senior Operations
| MXCT Stock | USD 3.52 0.14 4.14% |
Executive
Jay Gelfman is Senior Operations of MaxCyte
| Address | 9713 Key West Avenue, Rockville, MD, United States, 20850 |
| Phone | 301 944 1700 |
| Web | https://www.maxcyte.com |
MaxCyte Management Efficiency
The company has return on total asset (ROA) of (0.1125) % which means that it has lost $0.1125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.16) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.15 in 2024. Return On Capital Employed is likely to gain to -0.18 in 2024. At this time, MaxCyte's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 19.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 9.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| FACC MD | Nuwellis | N/A | |
| Amir Rippel | NanoVibronix | N/A | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Thomas Stankovich | ReShape Lifesciences | 63 | |
| Lindsey Harrison | NanoVibronix | N/A | |
| Paul Wotta | Nuwellis | 67 | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Michael Nketiah | Nexalin Technology | 48 | |
| Stephen CPA | NanoVibronix | 68 | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Indranil Dey | Bluejay Diagnostics | 61 | |
| Robert Scott | Nuwellis | 43 | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Al Diaz | ReShape Lifesciences | N/A | |
| Ryan McSeveney | Bluejay Diagnostics | N/A | |
| Lisa Wolf | Tivic Health Systems | 61 | |
| Carolyn Shelton | Nexalin Technology | 62 | |
| John Kowalczyk | Nuwellis | N/A | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| FACC MBA | Nuwellis | N/A | |
Management Performance
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 |
MaxCyte Leadership Team
Elected by the shareholders, the MaxCyte's board of directors comprises two types of representatives: MaxCyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MaxCyte. The board's role is to monitor MaxCyte's management team and ensure that shareholders' interests are well served. MaxCyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MaxCyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Brady, Senior Support | ||
| Stark Thompson, Consultant | ||
| Jill Mayer, Senior Resources | ||
| Cenk Sumen, Chief Officer | ||
| Douglas Doerfler, President, Founder | ||
| Jay Gelfman, Senior Operations | ||
| David Sandoval, General President | ||
| Thomas Ross, Executive Marketing | ||
| Ronald CPA, Executive Administration | ||
| Jack Horgan, Vice Development | ||
| Sarah Meeks, Senior Development | ||
| James Lovgren, VP Marketing | ||
| Maher Masoud, CEO, President | ||
| Sean Menarguez, Director Relations | ||
| CPA CFA, Chief Officer |
MaxCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MaxCyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (1.72) % | ||||
| Current Valuation | 233.16 M | ||||
| Shares Outstanding | 105.48 M | ||||
| Shares Owned By Insiders | 1.49 % | ||||
| Shares Owned By Institutions | 70.51 % | ||||
| Number Of Shares Shorted | 3.32 M | ||||
| Price To Book | 1.74 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.